Overview
Availability
- Dr Mark Effron is:
- Available for supervision
Works
Search Professor Mark Effron’s works on UQ eSpace
2025
Journal Article
PROGNOSTIC IMPLICATIONS OF PLATELET FCγRIIA DURING THE FIRST YEAR AFTER MYOCARDIAL INFARCTION
Schneider, David J., McMahon, Sean Robert, Angiolillo, Dominick J., Fanaroff, Alexander C., Wanamaker, Brett, Ibrahim, Homam, Effron, Mark B., Hohl, Patrick Kennedy, Shapiro, Timothy Alan, Ball, Kevin M. and DiBattiste, Peter M. (2025). PROGNOSTIC IMPLICATIONS OF PLATELET FCγRIIA DURING THE FIRST YEAR AFTER MYOCARDIAL INFARCTION. Journal of the American College of Cardiology, 85 (12), 1785. doi: 10.1016/s0735-1097(25)02269-7
2024
Conference Publication
Health System Variability in Lipid Management for Patients with Atherosclerotic Cardiovascular Disease: An Analysis from Cv-MOBIUS
Shah, Nishant, Shrader, Peter, Shoji, Satoshi, Martin, Seth, Fernandez, Soledad, Chamberlain, Alanna, Arnold, Jonathan, Shapiro, Michael, Effron, Mark, Chrischilles, Elizabeth, Allred, Clint, Priest, Elisa, Syed, Mahanaz, Kirchner, H Lester, Leja, Monika, Ahmad, Zahid, Kalich, Bethany, Dhalwani, Nafeesa, Jones, Laney, Wojcik, Cezary, Peterson, Eric and Navar, Ann Marie (2024). Health System Variability in Lipid Management for Patients with Atherosclerotic Cardiovascular Disease: An Analysis from Cv-MOBIUS. American Heart Association's 2024 Scientific Sessions and the American Heart Association's 2024 Resuscitation Science Symposium, Chicago, IL United States, 16–18 November 2024. Philadelphia, PA United States: Lippincott Williams & Wilkins. doi: 10.1161/circ.150.suppl_1.4145340
2024
Journal Article
Platelet fcγriia as a marker of cardiovascular risk after myocardial infarction
Schneider, David J., McMahon, Sean R., Angiolillo, Dominick J., Fanaroff, Alexander, Ibrahim, Homam, Hohl, Patrick K., Wanamaker, Brett L., Effron, Mark B. and DiBattiste, Peter M. (2024). Platelet fcγriia as a marker of cardiovascular risk after myocardial infarction. Journal of the American College of Cardiology, 84 (18), 1721-1729. doi: 10.1016/j.jacc.2024.08.051
2024
Journal Article
Contribution of clinical trial event data by data source a prespecified analysis of the ADAPTABLE randomized clinical trial
Rymer, Jennifer A., Mulder, Hillary, Wruck, Lisa M., Munoz, Daniel, Kripalani, Sunil, Effron, Mark B., Gupta, Kamal, Handberg, Eileen, Jain, Sandeep, Girotra, Saket, Whittle, Jeffrey, Hess, Rachel, Benziger, Catherine P., Knowlton, Kirk U., Curtis, Lesley H., Roe, Matthew T., Hammill, Bradley G., Rothman, Russell L., Harrington, Robert, Hernandez, Adrian and Jones, W. Schuyler (2024). Contribution of clinical trial event data by data source a prespecified analysis of the ADAPTABLE randomized clinical trial. JAMA Cardiology, 9 (9), E1-E6. doi: 10.1001/jamacardio.2024.2019
2024
Journal Article
Aspirin dosing for secondary prevention of atherosclerotic cardiovascular disease in male and female patients: A secondary analysis of the ADAPTABLE randomized clinical trial
Benziger, Catherine P., Stebbins, Amanda, Wruck, Lisa M., Effron, Mark B., Marquis-Gravel, Guillaume, Farrehi, Peter M., Girotra, Saket, Gupta, Kamal, Kripalani, Sunil, Munoz, Daniel, Polonsky, Tamar S., Sharlow, Amber, Whittle, Jeffrey, Harrington, Robert A., Rothman, Russell L., Hernandez, Adrian F. and Jones, W. Schuyler (2024). Aspirin dosing for secondary prevention of atherosclerotic cardiovascular disease in male and female patients: A secondary analysis of the ADAPTABLE randomized clinical trial. JAMA Cardiology, 9 (9) e006292, 808-816. doi: 10.1001/jamacardio.2024.1712
2024
Journal Article
Impact of aspirin dose according to race in secondary prevention of atherosclerotic cardiovascular disease: a secondary analysis of the ADAPTABLE randomised controlled trial
Marquis-Gravel, Guillaume, Mulder, Hillary, Wruck, Lisa M, Benziger, Catherine P, Effron, Mark B, Farrehi, Peter M, Girotra, Saket, Gupta, Kamal, Kripalani, Sunil, Muñoz, Daniel, Polonsky, Tamar S, Whittle, Jeff, Harrington, Robert, Rothman, Russell, Hernandez, Adrian F and Jones, WS (2024). Impact of aspirin dose according to race in secondary prevention of atherosclerotic cardiovascular disease: a secondary analysis of the ADAPTABLE randomised controlled trial. BMJ Open, 14 (8) e078197, e078197-8. doi: 10.1136/bmjopen-2023-078197
2024
Journal Article
Age and aspirin dosing in secondary prevention of atherosclerotic cardiovascular disease
Marquis‐Gravel, Guillaume, Stebbins, Amanda, Wruck, Lisa M., Roe, Matthew T., Effron, Mark B., Hammill, Bradley G., Whittle, Jeff, VanWormer, Jeffrey J., Robertson, Holly R., Alikhaani, Jacqueline D., Kripalani, Sunil, Farrehi, Peter M., Girotra, Saket, Benziger, Catherine P., Polonsky, Tamar S., Merritt, J. Greg, Gupta, Kamal, McCormick, Thomas E., Knowlton, Kirk U., Jain, Sandeep K., Kochar, Ajar, Rothman, Russell L., Harrington, Robert A., Hernandez, Adrian F. and Jones, W. Schuyler (2024). Age and aspirin dosing in secondary prevention of atherosclerotic cardiovascular disease. Journal of the American Heart Association, 13 (4) e026921, 1-9. doi: 10.1161/jaha.122.026921
2024
Journal Article
Characteristics and predictors of apparent treatment-resistant hypertension in real-world populations using electronic health record-based data
Jafari, Eissa, Cooper-DeHoff, Rhonda M., Effron, Mark B., Hogan, William R. and McDonough, Caitrin W. (2024). Characteristics and predictors of apparent treatment-resistant hypertension in real-world populations using electronic health record-based data. American Journal of Hypertension, 37 (1), 60-68. doi: 10.1093/ajh/hpad084
2024
Journal Article
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial
Narcisse, Dennis I., Kim, Hwasoon, Wruck, Lisa M., Stebbins, Amanda L., Muñoz, Daniel, Kripalani, Sunil, Effron, Mark B., Gupta, Kamal, Anderson, R. David, Jain, Sandeep K., Girotra, Saket, Whittle, Jeff, Benziger, Catherine P., Farrehi, Peter, Zhou, Li, Polonsky, Tamar S., Ahmad, Faraz S., Roe, Matthew T., Rothman, Russell L., Harrington, Robert A., Hernandez, Adrian F. and Jones, W. Schuyler (2024). Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial. Diabetes Care, 47 (1), 81-88. doi: 10.2337/dc23-0749
2023
Journal Article
More Potent Antiplatelet Therapy in Acute Coronary Syndrome Patients With Prior Stroke: Proceed With Caution?
McKinnie, Christopher M. and Effron, Mark B. (2023). More Potent Antiplatelet Therapy in Acute Coronary Syndrome Patients With Prior Stroke: Proceed With Caution?. Mayo Clinic Proceedings, 98 (11), 1590-1592. doi: 10.1016/j.mayocp.2023.09.014
2023
Journal Article
Aspirin dosing for secondary prevention of atherosclerotic cardiovascular disease in patients treated with P2Y12 inhibitors
Girotra, Saket, Stebbins, Amanda, Wruck, Lisa, Marquis‐Gravel, Guillaume, Gupta, Kamal, Farrehi, Peter, Benziger, Catherine P., Effron, Mark B., Whittle, Jeffrey, Muñoz, Daniel, Kripalani, Sunil, Anderson, R. David, Jain, Sandeep K., Polonsky, Tamar S., Ahmad, Faraz S., Roe, Matthew T., Rothman, Russell L., Harrington, Robert A., Hernandez, Adrian F. and Jones, W. Schuyler (2023). Aspirin dosing for secondary prevention of atherosclerotic cardiovascular disease in patients treated with P2Y12 inhibitors. Journal of the American Heart Association, 12 (20) e030385, 1-10. doi: 10.1161/jaha.123.030385
2023
Journal Article
Effectiveness and safety of enteric-coated vs uncoated aspirin in patients with cardiovascular disease: a secondary analysis of the ADAPTABLE randomized clinical trial
Sleem, Amber, Effron, Mark B., Stebbins, Amanda, Wruck, Lisa M., Marquis-Gravel, Guillaume, Muñoz, Daniel, Re, Richard N., Gupta, Kamal, Pepine, Carl J., Jain, Sandeep K., Girotra, Saket, Whittle, Jeffrey, Benziger, Catherine P., Farrehi, Peter M., Knowlton, Kirk U., Polonsky, Tamar S., Roe, Matthew T., Rothman, Russell L., Harrington, Robert A., Jones, W. Schuyler and Hernandez, Adrian F. (2023). Effectiveness and safety of enteric-coated vs uncoated aspirin in patients with cardiovascular disease: a secondary analysis of the ADAPTABLE randomized clinical trial. JAMA Cardiology, 8 (11), 1061-1069. doi: 10.1001/jamacardio.2023.3364
2023
Journal Article
Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE
Gupta, Kamal, Mehta, Harsh, Kim, Hwasoon, Stebbins, Amanda, Wruck, Lisa M., Muñoz, Daniel, Effron, Mark B., Anderson, R. David, Pepine, Carl J., Jain, Sandeep K., Girotra, Saket, DeWalt, Darren A., Whittle, Jeff, Benziger, Catherine P., Farrehi, Peter, Zhou, Li, Knowlton, Kirk U., Polonsky, Tamar S., Bradley, Steven M., Harrington, Robert A., Rothman, Russell L., Jones, W. Schuyler and Hernandez, Adrian F. (2023). Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE. American Heart Journal, 264, 31-39. doi: 10.1016/j.ahj.2023.06.001
2023
Journal Article
Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study
Chiarito, Mauro, Cao, Davide, Sartori, Samantha, Zhang, Zhongjie, Vogel, Birgit, Spirito, Alessandro, Smith, Kenneth F., Weintraub, William, Strauss, Craig, Toma, Catalin, DeFranco, Anthony, Effron, Mark B., Stefanini, Giulio, Keller, Stuart, Kapadia, Samir, Rao, Sunil V., Henry, Timothy D., Pocock, Stuart, Sharma, Samin, Dangas, George, Kini, Annapoorna, Baber, Usman and Mehran, Roxana (2023). Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study. European Heart Journal: Acute Cardiovascular Care, 12 (9), 594-603. doi: 10.1093/ehjacc/zuad083
2023
Journal Article
Novel tissue factor inhibition for thromboprophylaxis in COVID-19: primary results of the ASPEN-COVID-19 Trial
Hess, Connie N., Hsia, Judith, Carroll, Ian A., Nehler, Mark R., Ruf, Wolfram, Morrow, David A., Nicolau, Jose C., Berwanger, Otavio, Szarek, Michael, Capell, Warren H., Johri, Shilpa, Pursley, Michael S., Gupta, Ryan, Meehan, Patrick S., Franchi, Francesco, Effron, Mark B., Marshall, Debra, Graybill, Christopher A., Graybill, Sophie P., Keuer, Thomas, Bristow, Michael R. and Bonaca, Marc P. (2023). Novel tissue factor inhibition for thromboprophylaxis in COVID-19: primary results of the ASPEN-COVID-19 Trial. Arteriosclerosis, Thrombosis, and Vascular Biology, 43 (8), 1572-1582. doi: 10.1161/atvbaha.122.318748
2023
Journal Article
Internet versus noninternet participation in a decentralized clinical trial: lessons from the ADAPTABLE study
Shen, Rebecca, Mulder, Hillary, Wruck, Lisa, Weissler, E. Hope, Robertson, Holly R., Sharlow, Amber G., Kripalani, Sunil, Muñoz, Daniel, Effron, Mark B., Gupta, Kamal, Girotra, Saket, Whittle, Jeff, Benziger, Catherine P., VanWormer, Jeffrey J., Polonsky, Tamar S., Rothman, Russell L., Harrington, Robert A., Hernandez, Adrian F. and Jones, W. Schuyler (2023). Internet versus noninternet participation in a decentralized clinical trial: lessons from the ADAPTABLE study. Journal of the American Heart Association, 12 (13) e027899, 1-18. doi: 10.1161/jaha.122.027899
2023
Journal Article
Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): trial design and rationale
Joseph, Jacob, Pajewski, Nicholas M., Dolor, Rowena J., Sellers, Mary Ann, Perdue, Letitia H., Peeples, Sheronda R., Henrie, Adam M., Woolard, Nancy, Jones, W. Schuyler, Benziger, Catherine P., Orkaby, Ariela R., Mixon, Amanda S., VanWormer, Jeffrey J., Shapiro, Michael D., Kistler, Christine E., Polonsky, Tamar S., Chatterjee, Ranee, Chamberlain, Alanna M., Forman, Daniel E., Knowlton, Kirk U., Gill, Thomas M., Newby, L. Kristin, Hammill, Bradley G., Cicek, Mine S., Williams, Neely A., Decker, Jake E., Ou, Jiafu, Rubinstein, Jack, Choudhary, Gaurav ... Ramalingam, Ramesh (2023). Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): trial design and rationale. Journal of the American Geriatrics Society, 71 (6), 1701-1713. doi: 10.1111/jgs.18312
2022
Journal Article
Racial disparities and excess cardiovascular mortality before and during the COVID-19 pandemic: time for a solution
Obi, Koyenum and Effron, Mark B. (2022). Racial disparities and excess cardiovascular mortality before and during the COVID-19 pandemic: time for a solution. Mayo Clinic Proceedings, 97 (12), 2180-2183. doi: 10.1016/j.mayocp.2022.10.015
2022
Journal Article
Importance of More Potent Antiplatelet Therapy in Myocardial Infarction With Cardiac Arrest or Cardiogenic Shock
Effron, Mark B. (2022). Importance of More Potent Antiplatelet Therapy in Myocardial Infarction With Cardiac Arrest or Cardiogenic Shock. Mayo Clinic Proceedings, 97 (6), 1041-1043. doi: 10.1016/j.mayocp.2022.04.012
2022
Journal Article
Proposal for a simple algorithmic approach to manage drug-drug interactions of oral anticoagulants with nirmatrelvir/ritonavir in COVID-19 outpatients
Rizk, John G., Lazo, Jose G., Gupta, Aashish, Lavie, Carl J. and Effron, Mark B. (2022). Proposal for a simple algorithmic approach to manage drug-drug interactions of oral anticoagulants with nirmatrelvir/ritonavir in COVID-19 outpatients. Seminars in Thrombosis and Hemostasis, 49 (01), 085-088. doi: 10.1055/s-0042-1750024
Supervision
Availability
- Dr Mark Effron is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Media
Enquiries
For media enquiries about Dr Mark Effron's areas of expertise, story ideas and help finding experts, contact our Media team: